Related Experiment Videos

Risk factors for adenotonsillar hypertrophy in children following solid organ transplantation

Nina L Shapiro1, Ali M Strocker, Neil Bhattacharyya

  • 1Division of Head and Neck Surgery, UCLA School of Medicine, 62-158 CHS, 10833 LeConte Avenue, Los Angeles, CA 90095, USA. nshapiro@ucla.edu

Insights

Younger age and Epstein-Barr virus (EBV) seronegativity are key risk factors for adenotonsillar hypertrophy (ATH) in pediatric solid organ transplant recipients. ATH may precede PTLD, necessitating ongoing surveillance.

Area of Science:

  • Pediatric Transplant Medicine
  • Immunology
  • Otolaryngology

Background:

  • Post-transplantation lymphoproliferative disorder (PTLD) and its precursor, Epstein-Barr virus (EBV)-related lymphoid hyperplasia, can manifest in the tonsils and adenoids of pediatric solid organ transplant recipients.
  • Adenotonsillar hypertrophy (ATH) may represent an early sign of PTLD in this vulnerable population.

Purpose of the Study:

  • To identify clinical signs, symptoms, and risk factors associated with adenotonsillar hypertrophy (ATH) in children following solid organ transplantation.
  • To investigate the relationship between ATH and potential precursors to PTLD.

Main Methods:

  • A cross-sectional study was conducted with 132 pediatric solid organ transplant patients.
  • Data were collected through questionnaires, physical examinations, and laboratory tests.
  • Statistical analysis, including correlation and multivariate linear regression, was used to identify risk factors for ATH.

Main Results:

  • The study included 132 pediatric transplant recipients (64 renal, 68 liver) with a mean follow-up of 49 months.
  • A significant correlation was found between questionnaire scores and physical examination findings for ATH (Pearson's r=0.352, P<0.001).
  • Recipient EBV seronegativity and younger age at transplantation were identified as significant risk factors for ATH (P=0.024 and P=0.035, respectively).

Conclusions:

  • Younger age at transplantation and EBV seronegativity are significant risk factors for developing ATH in pediatric solid organ transplant recipients.
  • ATH may be an early indicator of PTLD, highlighting the need for long-term patient surveillance.
  • Further research is required to understand the impact of ATH on the quality of life and survival rates in these pediatric patients.
Abstract

Related Concept Videos